NASDAQ$TYRA
Tyra Biosciences Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Reported financial results for the second quarter of 2022 and highlighted recent corporate progress.
Tyra Biosciences reported a net loss of $15.1 million for the second quarter of 2022. The FDA cleared the company to proceed with its SURF301 study of TYRA-300, and the IND for TYRA-200 is on track to be filed in the second half of 2022. The company had cash and cash equivalents of $275.1 million as of Q2 2022.
- Received IND clearance from FDA to proceed with SURF301 Study of TYRA-300.
- Pipeline on track; IND for TYRA-200 to be filed in 2H 2022.
- The U.S. Food and Drug Administration (FDA) cleared TYRA to proceed with its Phase 1/2 SURF301 clinical study of TYRA-300.
- Strengthened Leadership Team with Key Hires.
Headline financials
Revenue & EPS history
Tyra Biosciences · Revenue · Quarterly
$0
Forward guidance
Statements contained in this press release regarding matters that are not historical facts are forward-looking statements.
Tailwinds
- Potential to develop purpose-built therapies that improve clinical outcomes
- Expected IND submission timing for TYRA-200.
- Ability to maintain undisrupted business operations due to the COVID-19 pandemic
- Ability to obtain and maintain intellectual property protection for our product candidates and proprietary technologies
- Developing a pipeline of selective inhibitors of Fibroblast Growth Factor Receptors (FGFR)
Headwinds
- Early in development efforts, have not tested any of product candidates in clinical trials
- Approach to discover and develop drugs based on SNÅP platform is novel and unproven
- Potential delays in the commencement, enrollment, and completion of preclinical studies and clinical trials
- Dependence on third parties in connection with manufacturing, research and preclinical testing
- Unexpected adverse side effects or inadequate efficacy of product candidates that may limit their development, regulatory approval, and/or commercialization
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2022
+2.0%
Avg return
Earnings day
+3.0%
Avg return
5 days after
-0.8%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+29.8%
Q3 2021
Best reaction
-11.5%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.5% | +7.7% | +21.8% | |
| Q3 2025 | +0.3% | +8.4% | +50.6% | |
| Q2 2025 | +0.4% | -4.3% | +17.0% | |
| Q1 2025 | -3.1% | -4.0% | +2.3% | |
| Q4 2024 | -0.8% | -10.5% | +3.9% | |
| Q3 2024 | -5.9% | -6.9% | -8.1% | |
| Q1 2024 | -3.8% | +3.1% | +9.7% | |
| Q4 2023 | +7.0% | +3.0% | -9.7% | |
| Q3 2023 | -6.3% | -8.1% | +2.5% | |
| Q2 2023 | +0.9% | +1.6% | -3.4% | |
| Q1 2023 | -3.3% | +7.0% | +13.1% | |
| Q4 2022 | -3.3% | +0.0% | -9.8% | |
| Q3 2022 | -7.1% | +12.9% | -3.1% | |
| Q2 2022 | +11.1% | +14.7% | -24.0% | |
| Q1 2022 | +0.1% | -5.9% | -17.8% | |
| Q4 2021 | -11.5% | -5.3% | -6.4% | |
| Q2 2021 | +29.8% | +20.3% | -26.6% | |
| Q3 2021 | +29.8% | +20.3% | -26.6% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro